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Abstract The pathological diagnosis of adrenocortical
carcinoma (ACC) is still challenging for its rarity and the
presence of special variants (pediatric, oncocytic, myxoid,
and sarcomatoid). It is based on the recognition at light
microscopy of at least three among nine morphological
parameters, according to the Weiss scoring system, which
has been introduced 27 years ago and nowadays is the most
widely employed. Nevertheless, the diagnostic performance
of this system is very high but does not reach a sensitivity
and specificity of 100%, its diagnostic applicability is
potentially low among non-expert pathologists, and a group
of borderline cases with only one or two criteria exist of
uncertain behavior. Moreover, it is scarcely reproducible in
the ACC morphological variants. In fact, specifically for the
pure oncocytic neoplasms that seem to have a better
prognosis in comparison to the conventional ACCs, a
modified system (the Lin–Weiss–Bisceglia) has been
proposed. With the aim to simplify the ACC diagnosis,
2 years ago, the “reticulin” diagnostic algorithm has been
proposed, based on the observation that the tumoral
reticulin framework (highlighted by reticulin silver-based
histochemical staining) is consistently disrupted in malig-
nant cases but only in a small subset of benign cases.
Following this algorithm, in the presence of reticulin
alterations, malignancy is further defined through the
identification of at least one of the following parameters:
necrosis, high mitotic rate, and venous invasion. As a
complement to the morphological approach, some immu-
nohistochemical markers (such as steroidogenic factor 1)
have been proposed as diagnostic and prognostic adjuncts
but still lack wide clinical validation.
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Introduction
Adrenocortical cancer (ACC) is a rare and aggressive
disease with an incidence of approximately one case per
million. The presence of distant metastases at the time of
diagnosis is relatively common, and its differential diagno-
sis in this clinical situation is mainly related to the
exclusion of other malignant neoplasms metastatic to the
adrenal, especially in inoperable cases [12]. However, due
to the growing incidence of adrenal nodules discovered
incidentally during radiological procedures for unrelated
clinical conditions, the proportion of cases confined to the
adrenal is increasing, together with the diagnostic difficul-
ties in differentiating benign from malignant adrenocortical
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neoplasms [14]. In fact, at variance with other endocrine
tumors (i.e., follicular tumors of the thyroid), the patholog-
ical diagnosis of “carcinoma” does not rely on clear-cut
morphological parameters but mostly on a combination of
multiple features suggestive, but not pathognomonic per se,
of malignancy [22]. Therefore, in the last decades, variable
combinations of such parameters in different scoring
systems have been proposed in the literature [21, 43] being
the scoring method proposed by Weiss in 1984 [48] with
subsequent modifications [49] and revisions [2] by far the
most widely employed.
The Weiss Scoring System
The Weiss scoring system is based on the recognition at
light microscopy of nine morphological parameters: three
of them are related to tumor structure, namely presence of
eosinophilic (“dark”) cytoplasm in more than 75% of tumor
cells, of a “patternless” diffuse architecture, and of necrosis;
three others are related to cytological features, namely
presence of nuclear atypia, of mitotic index above 5 per 50
high-power fields, and of atypical mitoses; the remaining
three are related to invasive tumor properties, including
sinusoidal, venous, and capsular invasion (Table 1). A
diagnosis of malignancy is achieved if at least three
parameters are identified. Although the recognition of each
of these parameters is based on well-defined and stringent
morphological criteria [23], in the general practice, the
diagnostic applicability of the Weiss system is not always
easy since some of these features (diffuse growth, necrosis,
sinusoidal, vascular and capsular invasion, nuclear atypia)
are subjective (in terms of presence and/or quantification)
or biased by the adequacy of tumor sampling [46].
Moreover, the diagnostic performance is very high but
does not reach a sensitivity and specificity of 100%. In
order to simplify the diagnostic approach and improve the
diagnostic performance of the Weiss system, some mod-
ifications have been proposed in the past, including a
statistically modified system based on the most reliable
criteria [2] that take into account mitotic rate and dark
cytoplasm (both scored 2), and abnormal mitoses, necrosis,
and capsular invasion (scored 1 each), with an overall
cutoff score for malignancy set at 3. However, although
such modifications intended to implement the accuracy of
ACC pathological diagnosis, they have been validated only
in one further study [43] and did not replace the classical
Weiss system in the common clinical practice.
Diagnostic Reproducibility
As discussed above, not all diagnostic features considered
in the Weiss scoring system are easy to recognize and
apply, and therefore, a major limitation in the diagnostic
applicability of the Weiss score is related to its potentially
low reproducibility. Few studies aimed at investigating the
inter-observer agreement among pathologists. In the revis-
itation by Aubert and coworkers [2], inter-observer agree-
ment for the total Weiss score was excellent (r=0.94)
among experts, but this is apparently not so straightforward
in the common practice.
A program that aimed at harmonizing and improving the
performance of the pathological diagnosis of adrenal cortical
tumors in France, through the National INCa-COMETE
(Institut National du Cancer-COrtico-MEdullo Tumeurs
Endocrines) Network, was initiated. Pathologists from all
reference centers of the National INCa-COMETE Network
analyzed 50 adrenal cortical tumors, using a web-based
virtual slide system, in a blind design allowing to determine
the intra- and inter-observer reproducibility of the Weiss
scoring system before and after a coaching meeting was
organized to harmonize and improve analyses (USCAP
Washington 2010, online communication and paper in
preparation).
The Problem of Borderline Cases
In the majority of cases, the differential diagnosis between
adrenocortical adenoma and carcinoma is easy to assess [22].
The vast majority of adenomas consistently lack all Weiss
parameters, whereas most cases of adrenocortical carcinoma
(62% in a series of 201 cases from Turin; Table 2) have a
Weiss score of 6 or higher, thus being easily recognized as
malignant. However, in some cases (approximately up to
Table 1 The Weiss system
Histological criteria Weight of criteria
0 1
Nuclear gradea 1 and 2 3 and 4
Mitoses ≤5 for 50 fields ×400 ≥6 for 50 fields ×400
Atypical mitoses No Yes
Clear cells >25% ≤25%
Diffuse architecture ≤33% surface >33% surface
Confluent necrosis No Yes
Venous invasion No Yes
Sinusoidal invasion No Yes
Capsular infiltration No Yes
The presence of three or more criteria highly correlates with
malignancy [46]
aAccording to Fuhrman criteria [17]: grade 1 (round nuclei, homoge-
nous, small size, no nucleoli), grade 2 (nuclei slightly irregular, more
voluminous, conspicuous nucleoli at ×400), grade 3 (irregular nuclei,
voluminous nucleoli at ×100), grade 4 (idem grade 3 with monstrous
cells with very irregular nuclei)
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10% of adrenal cancer series in the Authors’ personal
experience), only one or two Weiss parameters are recog-
nized, with a final score not sufficient for a diagnosis of
malignancy, but suggestive of a malignant potential,
although uncertain. These cases are worrisome from both
pathological and clinical standpoints since these, on the one
hand, underline the need of a more unequivocal pathological
classification and, on the other, pose questions on their
appropriate clinical management and follow-up. In most of
such “borderline” cases, the commonly recognized Weiss
parameters include one or two of the following: nuclear
atypia, eosinophilic cytoplasm, diffuse growth, or sinusoidal
invasion. These are parameters that generally have the lowest
specificity when correlated to malignant behavior; by
contrast, conventional malignancy-related parameters, such
as high mitotic index, atypical mitoses, necrosis, vascular
and capsular invasion, are usually not occurring alone, but
are rather combined with other parameters, thus easily
determining a high Weiss scores [46]. A possible exception
is represented by early incidentally detected ACCs that may
have small size and, although in the presence of mitotic
activity, might lack signs of invasion that usually develop
later during tumor progression. Based on the above com-
ments, a diagnosis of “borderline” or “uncertain malignant
potential” tumor should be rendered only after extensive
tumor sampling and evaluation of an adequate number of
histological sections.
Adrenocortical Carcinoma Variants
Pediatric Tumors
Pediatric adrenocortical tumors are even more rare than their
adult counterpart and, although the majority of cases show
morphological features related to malignancy, usually present
a less aggressive clinical behavior [23]. Very few studies have
addressed this issue in a consistent number of cases, being
the AFIP series with 83 pediatric tumors the largest one [50].
In this study, among the classical criteria considered in the
Weiss system, only confluent necrosis, capsular or vascular
invasion, presence of atypical mitotic figures, and a mitotic
count >15 per 20 high-power fields were significantly related
to poor prognosis. Conversely, some others, such as
eosinophilic cytoplasm, diffuse architecture, or sinusoidal
invasion, were apparently less relevant. Four additional
parameters also had a relevant impact on prognosis,
including tumor weight >400 g, tumor size >10.5 cm, vena
cava invasion, and periadrenal tissue infiltration.
Oncocytic Tumors
This term refers to a subset of adrenocortical tumors with a
predominant component of large, deeply eosinophilic,
mitochondrion-rich cells. As originally stated by Bisceglia
and coworkers [4], the diagnosis of malignancy in oncocytic
tumors is difficult using the classical Weiss scoring system
since at least three parameters (eosinophilic cytoplasm, high
nuclear grade, and diffuse architecture) are intrinsically
present in this tumor type, irrespective of the biological and
clinical behavior. Therefore, the cutoff values validated for
conventional adrenocortical carcinoma may lead to an
overdiagnosis of malignancy in this special group. Modified
scoring systems which separately analyze “major” (mitotic
index, atypical mitoses, and venous invasion) and “minor”
(necrosis, capsular and sinusoidal invasion, size >10 cm, and
weight >200 g) criteria have therefore been proposed to
define three groups of tumors (benign, borderline, and
malignant) that possess distinct clinical behavior [52].
Myxoid Tumors
Focal extracellular deposits of myxoid material, highlighted
by positive Alcian-Blue staining, are not uncommon in
Table 2 Descriptive clinical and pathological features in an Italian
cohort of adrenocortical carcinomas
No. of cases 201
F/M 118/83
Mean age (range) 47 (3–85)
Functional status (known in 157 cases)
Not functioning 76
Cortisol 52
Cortisol+androgens 10
Androgens/estrogens 6/2
Aldosterone 6
“Hypertension” 5
Follow-up (known in 188 cases)
NED/DOC 69
AWD 47
DOD 72
Location left/right adrenal (known in 179 cases) 102/75a
Mean size, cm (range) 11.3 (1.6–28)
Mean weight, g (range) 480 (8–4,000)
Mean Weiss score 6.25b
Weiss score 3–5/6–9 71/118b
Pediatric 1
Myxoid variant 20
Oncocytic variant 22
Sarcomatoid variant 0
NED no evidence of disease, AWD alive with disease, DOC died of
unrelated causes, DOD died of disease
a Two bilateral tumors
b Not applicable in 12 cases because of metastases, biopsies, post-
chemotherapy, or radiotherapy
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adrenocortical benign and malignant neoplasm, but they
may be predominant in a subset of approximately 10% of
ACC [31]. In such cases, especially in biopsy material, a
distinction from extraskeletal myxoid chondrosarcoma,
chordoma, myxoid carcinomas from the kidney or other
sites, myxoid lipomatous, or nerve sheet tumors should be
taken into account. Moreover, the distinction between
benign and malignant adrenocortical myxoid tumors may
be worrisome. In a recent series of 14 cases reported by our
group [31], we could observe that most cases were
characterized by a trabecular, chordonal, or micro-alveolar
growth of small cells with absent or mild nuclear
pleomorphism, thus lacking two Weiss parameters (diffuse
growth and nuclear atypia). Moreover, the identification of
invasive areas might be equivocal due to the presence of
abundant myxoid background. Therefore, it is advisable in
adrenal tumors with predominant myxoid stroma to suspect
malignancy even in tumors with an apparently low grade
appearance.
Sarcomatoid Carcinoma
This adrenocortical carcinoma variant is extremely rare, and
to our knowledge, only nine cases have been reported in the
literature so far [3, 8, 9, 10, 16, 24, 30, 33, 38]. This tumor
type is aggressive, and the recognition of diagnostic
features of malignancy is not problematic.
Beyond the Weiss Score
As also stated above, the diagnostic work-up of adrenocor-
tical tumors is still time-consuming and poorly reproduc-
ible. An alternative view to the use of diagnostic scoring
systems (the Weiss or others) is the definition of algorith-
mic approaches based on the recognition of the most
relevant pathological features, such as mitotic index, and
the exclusion of less sensitive or poorly specific or
equivocal features. Following this alternative approach, in
2007, a study suggested to select malignant cases through a
diagnostic algorithm based on mitotic count (>5/50 HPF),
followed by the recognition of other parameters (including
nuclear grade, diffuse growth pattern, and tissue reaction)
[5]. A comparison with the other known scoring systems
indicated that a stepwise procedure was the most specific,
while the pathological scores proposed in Weiss and van-
Slooten systems were the most sensitive for adrenocortical
carcinoma diagnosis.
Two years later, we proposed a diagnostic algorithm
based on the observation that the disruption of the reticulin
framework (highlighted by reticulin silver-based histo-
chemical staining) is a consistent finding in ACC and is
only occasionally encountered in benign (Weiss score ≤2)
adrenocortical tumors [45]. This histochemical feature was
therefore considered as the primary step for the recognition
of malignancy. The additional presence of at least one of
the malignancy-related criteria conventionally considered in
several endocrine tumors (necrosis, mitotic rate >5/50 HPF,
as in the Weiss system, and venous vessel invasion) raised
up to 100% the sensitivity and specificity of the proposed
algorithm for a diagnosis of malignancy in a series of 92
cases. This simplified scheme has the major advantage of
reducing the analysis of other parameters such as nuclear
atypia, eosinophilic cytoplasm, sinusoidal and capsular
invasion, that, although commonly found in malignant
lesions, may be of equivocal definition and are sometimes
subjective. In addition, it has been validated in our
extended and updated (April 2011) Turin series of 201
ACC, but not in external series, yet.
Minimal Requirements for Pathological Reporting
One of the most relevant issues in ACC diagnosis is the
lack of homogeneity and standardization in pathological
reporting. Several papers and recommendations highlighted
the need of referral centers for ACC diagnosis, but even in
centers of excellence, a standardization of the diagnostic
procedure and reporting is not uniformly accepted. It is the
common opinion of these Authors that a minimal dataset of
information should be included in the pathological report of
any ACC case (Table 3).
Table 3 Minimal requirements for pathological reporting
Macroscopy (one paraffin inclusion×cm, with special reference to the
capsule/invasive front)
- Integrity of the sample, including tumor surface
- Size (three dimensions) and weight
- Description of the cut surface
- Description of the tumor borders, including presence and integrity of
the tumor capsule, adhesion/invasion of adjacent tissues/structures
- Presence of residual adrenal tissue
Microscopy
- Type of scoring system applied (Weiss system to be preferred)
- Description of each individual parameter considered (mandatory to
specify the numerical value of mitotic index in 50 high-power fields)
- Status of the resection margins
- Immunoprofile, if performed
- Ki-67 labeling indexa
Diagnosis
- Diagnosis, including variants
- pTNM stage (specify which, for example, AJCC/WHO or ENSAT) [13]
a Based on recent literature data and according to the Hôpital Cochin
experience, some more immunohistochemical markers may be added
but are still not recommended in the daily practice, and include p53,
cyclin E, and beta-catenin
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The Need of a Grading System
Apart from diagnostic consideration, a critical reappraisal
of the most relevant pathological parameters in ACC
diagnosis led to the recognition that some of them have a
prognostic impact being their expression also correlated to
survival. In this respect, a study by Assie and coworkers
was reported on 124 metastatic cases [1] and claimed the
importance of high mitotic index (and the presence of
atypical mitotic figures) as the most relevant factor
significantly correlated with clinical aggressiveness and
poor survival. This same observation was also confirmed
by other studies although with heterogeneous cutoff values
[20, 28, 45] and supports the concept that a grading system
based on mitotic count might help in the prognostic
stratification of patients [19].
Molecular Markers in the Diagnosis and Prognosis
of ACC
Apart from the prognostic impact of mitotic count already
discussed above, none of the pathological parameters
commonly used for the definition of malignancy in
adrenocortical tumors is associated to a specific clinical
behavior. A value of the total Weiss score to predict the
clinical outcome has been postulated by some authors [44],
but does not reflect our personal experience [45]. Some
immunohistochemical markers were shown to be indepen-
dent predictors of clinical aggressiveness, including—
among the most recent—matrix metalloproteinase type 2
[47], glucose transporter 1 [15], and steroidogenic factor 1
(SF-1) [35]. However, none of them has been validated
enough to be considered a novel potential prognostic
biomarker in ACC. Therefore, molecular strategies are
expected to better depict the molecular pathways responsi-
ble for adrenal cancer onset and progression and to identify
new markers and possible therapeutic targets.
Ki-67 Proliferation Index
Ki-67 proliferation index study can bring additional help
for establishing malignancy diagnosis (Fig. 1). A prolifer-
ation index over 5% has only been observed in ACC [27],
but ACC with low proliferation index can exist, parallel to
those observed in adrenocortical adenoma (ACA) [27, 29,
37]. Some papers [29, 39] reported that a high level of Ki-
67 seems to correlate with a shortness disease survival and
maybe useful as a marker of worse prognosis. However, at
present for adrenocortical neoplasms, variability in Ki-67
staining procedure and evaluation might be responsible for
poor standardization and applicability of this marker as a
diagnostic tool, and detailed recommendation is therefore
needed. In our opinion, it seems reasonable to recommend
Fig. 1 Adrenocortical carcino-
ma, morphological and
immunophenotypical patterns.
Hematoxylin–eosin (a, ×200),
immunohistochemical staining
for SF-1 (b, ×200), Ki-67
(c, ×200), for p53 (d, ×200),
cyclin E (e, ×200), and
β-catenin (f, ×200)
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the use of MIB-1 antibody clone and the expression of the
proliferation index as a percentage of positive nuclei after
counting 500–2,000 cells in the areas of strongest nuclear
labeling, as suggested for neuroendocrine neoplasms [6].
P53
Germline mutation of the tumor suppressor gene TP53 is
responsible for the Li–Fraumeni syndrome, a syndrome that
can include ACC. Somatic TP53 mutations are found in
25–30% of sporadic ACC, but not in ACA. Positive p53
immunohistochemistry is well correlated with the presence
of TP53 mutation in ACC [26]. In particular, ACC
harboring TP53 mutation were associated with a more
advanced stage of tumor progression and had a shorter
disease-free survival [25]. More recently, these data have
been confirmed by Ragazzon et al. [32], demonstrating that
the p53 pathway is involved in the pathogenesis of ACC
with poor prognosis. Immunohistochemistry study for p53
has thus a limited interest for evaluating malignancy
because despite a good specificity, few ACC are positive,
but it is of interest to evaluate the prognosis of ACC.
IGF-II
It can be interesting to try to evaluate insulin-like growth factor
II (IGF-II) by immunohistochemistry because overexpression
is observed in 90% of ACC and almost none in ACA. A few
studies have been performed [36, 51]. Wilkin et al. have
reported four pediatric ACC that were all positive for IGF-II
[51]. Schmitt et al. have reported 22 ACA and 17 ACC; 76%
of the ACC were IGF-II positive with a dot perinuclear
labeling, whereas no ACA were positive [36]. Wilkin et al.
[51] used a classical method of labeling, whereas Schmitt et
al. [36] revealed the labeling by intensification with cobalt
ions. The difficulty to show the labeling might explain why
anti-IGF-II antibody is not widely used [40].
Cyclin E
It has been shown in ACT overexpressing IGF-II gene that
G1 cyclins and cyclin-dependent kinase (CDK) production,
including cyclin E and CDK2, were positively regulated
[7]. By immunohistochemistry, Tissier et al. showed that
ACC overexpress cyclin E (5%) contrary to ACA and that
cyclin E overproduction was significantly associated with
shorter disease-free survival in univariate analysis, demon-
strating its adverse prognostic significance [42].
β-Catenin
Activation of theWnt/β-catenin signaling pathway is frequent
in ACC, and can be associated to somatic β-catenin gene
mutation [41]. This leads to β-catenin accumulation,
demonstrated by immunohistochemistry [41].
Moreover, it has been demonstrated that Wnt/β-catenin
activation, confirmed by the presence of β-catenin nuclear
staining, is associated with a more aggressive phenotype
and is an independent prognostic factor of overall and
disease-free survival in patients with resected primary ACC
[18].
Steroidogenic Factor-1
In the past, SF-1 has been suggested as a marker to
differentiate between tumors of adrenocortical and non-
adrenocortical origin [34]. Recent studies have demonstrat-
ed overexpression of SF-1 in most cases of childhood
adrenocortical tumors [11]. Moreover, Sbiera et al. [35]
confirmed that SF-1 is a highly valuable immunohisto-
chemical marker to determine the adrenocortical origin of
an adrenal mass and demonstrated that SF-1 expression is
of stage-independent prognostic value in patients with
ACC.
Conclusion
The Weiss system is considered the mainstay in differen-
tiating the benign and malignant adrenocortical tumors in
the adult population [23, 48, 49]. Although the Weiss
system is largely used in assessing malignancy in adreno-
cortical tumors, some limits to its use are still open. For
these reasons, new tools are necessary in order to solve
some important issues as: (1) the borderline cases and (2)
the ACC variants. In particular, important advances are
made in the physiopathology of the adrenocortical tumors
thanks to genetic studies, and this allowed to identify new
molecular markers useful also in the immunohistochemical
diagnosis.
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